lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
== Medical uses == Clascoterone is indicated for the topical treatment of acne vulgaris in people aged twelve years of age and older. Two large phase III randomized controlled trials evaluated the effectiveness of clascoterone for the treatment of acne over a period of 12 weeks. Clascoterone decreased acne symptoms by about 8 to 18% more than placebo. The defined treatment success endpoint was achieved in about 18 to 20% of individuals with clascoterone relative to about 7 to 9% of individuals with placebo. The comparative effectiveness of clascoterone between males and females was not described.
== Related conditions == Disorders that are clinically similar are konzo and Lytico-bodig disease. Konzo means "tied legs" in the Yaka language, and is common in some African people in central and eastern parts of the continent who are consuming diets poor in protein. The possible molecule causing this problem is thiocyanate, which stimulates AMPA receptors.
One of the important functions of an FSL construct is that it can optimise the presentation of antigens, both on cell surfaces and solid-phase membranes. This optimisation is achieved primarily by the spacer, and secondarily by the lipid tail. In a typical immunoassay, the antigen is deposited directly onto the microplate surface and binds to the surface either in a random fashion, or in a preferred orientation depending on the residues present on the surface of this antigen. Usually this deposition process is uncontrolled. In contrast, the FSL Kode construct bound to a microplate presents the antigen away from the surface in an orientation with a high level of exposure to the environment. Furthermore, typical immunoassays use recombinant peptides rather than discrete peptide antigens. As the recombinant peptide is many times bigger than the epitope of interest, a lot of undesired and unwanted peptide sequences are also represented on the microplate. These additional sequences may include unwanted microbial related sequences (as determined by a BLAST analysis) that can cause issues of low level cross-reactivity. Often the mechanism by which an immunoassay is able to overcome this low level activity is to dilute the serum so that the low level microbial reactive antibodies are not seen, and only high-level specific antibodies result in an interpretable result.
In response to the attacks, Hezbollah made its deepest incursion into Israeli territory at the time by launching drone attacks into the city of Acre targeting two IDF bases. On 5 May, an Israel airstrike on a house in the Lebanese village of Meiss Ej Jabal killed four civilians. In retaliation, Hezbollah fired dozens of rockets at the Israeli town of Kiryat Shmona. On 6 May, two reservist Israeli soldiers of the 98th Paratroopers Division's 655th Battalion were killed by a Hezbollah drone attack near Metula, northern Israel, bringing the IDF death toll to 18. Hezbollah also launched 30 rockets at the Golan Heights, damaging houses in Kidmat Tzvi. The IDF struck 15 Radwan targets in al-Lwaiza, southern Lebanon, and a Hezbollah compound in Sefri, near Baalbek. Lebanese media said that the strike destroyed a factory and injured three people. On 8 May, Israeli airstrikes in southern Lebanon killed two Hezbollah and three PIJ members. The next day an Israeli airstrike on a car near the village of Bafliyeh killed four Hezbollah members. On 10 May, Israeli airstrikes on two villages in the Marjeyoun District killed a Hezbollah member in Aedsheet and a PIJ member in Blida, respectively. On the same day, another Israeli airstrike on the town of Tayr Harfa killed two civilians who were carrying out repairs on a local cell tower. On 14 May, an Israeli airstrike on a house in the village of Meiss Ej Jabal killed a member of Hezbollah and injured one other person.
Sources: en.wikipedia.org
== Names == Dapagliflozin is the international nonproprietary name (INN), and the United States Adopted Name (USAN). The fixed-dose combination product, dapagliflozin/metformin extended-release, is sold under the brand name Xigduo XR. In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was authorized for medical use in the European Union and is sold under the brand name Qtern. The combination drug was approved for medical use in the United States in February 2017, where it also is sold under the brand name Qtern. In May 2019, the fixed-dose combination of dapagliflozin, saxagliptin, and metformin hydrochloride as extended-release tablets was approved in the United States to improve glycemic control in adults with type 2 diabetes when used in combination with diet and exercise. The FDA granted the approval of Qternmet XR to AstraZeneca. The combination drug was authorized for use in the European Union in November 2019, and is sold under the brand name Qtrilmet.
=== High-salt liquid-state fermented soy sauce === High-salt liquid-state fermentation (HLF) of soybeans depends heavily on microbial activity, metabolism and enzymatic hydrolysis of macronutrients. Most traditional approaches fall into the scope of HLF.
Because the molecular weight of endotoxins is usually over 10 kD, ultrafiltration can sometimes be used to perform as a size based separation. Due to the high variability of endotoxin size, it can be difficult to select the correct membrane, hence this method is best used only when all endotoxins present are larger than 300,000 Da. Commercially available ultra filters have been shown to remove pyrogens to a level below 0.001 EU/ml.
88 percent of teleost species are gonochoristic, having individuals that remain either male or female throughout their adult lives. The sex of an individual can be determined genetically as in birds and mammals, or environmentally as in reptiles. In some teleosts, both genetics and the environment play a role in determining sex. For species whose sex is determined by genetics, it can come in three forms. In monofactorial sex determination, a single-locus determines sex inheritance. Both the XY sex-determination system and ZW sex-determination system exist in teleost species. Some species, such as the southern platyfish, have both systems and a male can be determined by XY or ZZ depending on the population. Multifactorial sex determination occurs in numerous Neotropical species and involves both XY and ZW systems. Multifactorial systems involve rearrangements of sex chromosomes and autosomes. For example, the darter characine has a ZW multifactorial system where the female is determined by ZW1W2 and the male by ZZ. The wolf fish has a XY multifactorial system where females are determined by X1X1X2X2 and the male by X1X2Y. Some teleosts, such as zebrafish, have a polyfactorial system, where there are several genes which play a role in determining sex. Environment-dependent sex determination has been documented in at least 70 species of teleost. Temperature is the main factor, but pH levels, growth rate, density and social environment may also play a role. For the Atlantic silverside, spawning in colder waters creates more females, while warmer waters create more males.
== History == Diabulimia is not currently recognised in the DSM-5. Current diagnoses are based on the idea of insulin restriction being a feature of existing anorexia nervosa and bulimia nervosa. Diabulimia is gaining notability within scientific research. In 2019, NHS England began trialling specialist diabulimia clinics. Whilst access to eating disorder clinics is improving, access to specialist diabulimia services is not widely available.
Sources: en.wikipedia.org
=== Human chorionic gonadotropin === Human chorionic gonadotropin (hCG) is a hormone produced by the placenta during pregnancy. This hormone stimulates the Corpus Luteum to produce progesterone to maintain pregnancy. Therefore, hCG plays a role in human maternal recognition of pregnancy.
Many people with MCT8 deficiency experience a range of debilitating effects, including the inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties and chronic stress on the heart and metabolism.
=== Puerto Rico === Chick-fil-A opened its first location in Puerto Rico in 2022 and by 2024 had expanded to seven restaurants, with the plan for up to 25 locations by 2030. The unique menu includes coffee 100% grown and roasted in Puerto Rico.
1995 membership 1,789. Grants scholarships and donations to St. Tikhon's Seminary and Monastery, St. Vladimir's Orthodox Theological Seminary; and the Monastery of the Transfiguration, Orthodox Press Fund, Alaskan Fund and the UPMC Children's Hospital of Pittsburgh.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.